Patent ID: 8901110

Claim:
A method of treating hepatocellular carcinoma, comprising: identifying a subject having hepatocellular carcinoma who is likely to be responsive to a treatment compound, comprising: a) determining the level of a biomarker in a hepatocellular carcinoma cell-containing sample from the subject, wherein the biomarker is selected from the group consisting of TCF-4, WISP2, ASPH, IRS1, MAPK12, CLDN2, JAG1, GPR56, ANXA1, CAMK2N1, STK17B, SPP1, AXIN2, MMP7, CADM1, PLCD4, CD24, and combinations thereof; and b) comparing the level of the biomarker in the sample to a reference level of the biomarker; wherein the subject is likely to be responsive to the treatment if the level of the biomarker in the sample of the subject is higher than the reference level of the biomarker, wherein the reference level is a level determined from a sample containing no hepatocellular carcinoma cells; and administering a therapeutically effective amount of the treatment compound to the subject identified to be likely to be responsive to the treatment; wherein the hepatocellular carcinoma is poorly differentiated hepatocellular carcinoma; and wherein the treatment compound is thalidomide, lenalidomide, pomalidomide, or 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.